NovaBiotics Logo

NovaBiotics Ltd
Cruickshank Building
Craibstone
Aberdeen
AB21 9TR
UK

 

 

 

Courtesy of Robert Koch Institute

 

Courtesy of CDC

Latest News

Feb 2010

NovaBiotics scientist to run Edinburgh Marathon for The CF Trust (23rd May)


20/1/10

Clinical development success for NovaBiotics - Life Sciences Scotland News, Issue 48


11/1/10

NovaBiotics attending PepTalk 2010 in San Diego


4/1/10

NovaBiotics prepares to out-license nail product - The Herald


20/11/09

NovaBiotics nears licensing deal for topical antifungal candidate - SCRIP


20/11/09

Initial Phase IIa clinical data for Novexatin® supports Phase I findings


4/11/09

First Phase IIa patients complete trial successfully


3/11/09

NovaBiotics a step closer to licensing - The Scotsman


1/11/09

Fungus Nailed - The Times


Enterprise Scotland Magazine - NovaBiotics Article


27/10/09

Bio-Europe 2009 - NovaBiotics' Profile


01/10/09

Novexatin® Phase IIa study commences


09/09/2009

Official launch of the science behind Novexatin® at ICAAC, San Francisco on 13th September 2009


01/09/2009

Positive Phase 1 clinical data for nail fungus treatment, Novexatin®


25/08/2009

Phase 1 Clinical Study for Novexatin® Concludes


21/08/2009

NovaBiotics selected to present data at high profile, international events


06/07/2009

Clinicial trials commencing for NovaBiotics' nail fungus treatment, Novexatin®


01/07/2009

NovaBiotics Reaches Financing Target set for H1 2009


29/05/2009

NovaBiotics attends BIO-2009


23/03/2009

NovaBiotics Ltd raise £451 and counting for Red Nose Day 2009!


12/02/2009

Further funding secured in a key year for "clinic-ready" Novabiotics


06/02/2009

NovaBiotics Ltd wins Rising Star Award at the BioIndustry Association Thistle Bioscience Forum


26/01/2009

NovaBiotics to present at the BIA Scotland Thistle Bioscience Showcase 2009


24/11/2008

NovaBiotics Contract Research


15/10/2008

Preclinical Development of Novexatin™ Complete


14/10/2008

NovaBiotics attends ICAAC 2008


04/10/2008

New Appointments at NovaBiotics


04/10/2008

Completion of Interim Fundraising


30/09/2008

Luminaderm®

NovaBiotics is a clinical stage biotechnology company based in Aberdeen and was founded in 2004. Its unique patented peptide anti-infective technology has already demonstrated enhanced efficacy, safety and bioavailability over current and emerging competition as well as the potential for a fast-track route to market and revenue initially through its first application, a topical (brush on) treatment for fungal nail infections (NP213/Novexatin®).

 

 

Registered in Scotland No. SC272344. Registered Address: NovaBiotics Ltd, Cruickshank Building, Craibstone, Aberdeen, AB21 9TR, UK

© NovaBiotics Ltd 2009. All Rights Reserved
Last updated 8 February, 2010

Investors in People